Reimbursement Delays: Still Variable, Getting Even More So
Executive Summary
The EU enlargement project may have just taken a big step forward, but when it comes to harmonization, there's still work to do. One of the most challenging aspects to doing business in Europe for pharma firms remains the complex and lengthy pricing and reimbursement negotiations required in each market in order to get drugs to patients. Despite EU guidelines limiting the reimbursement delay period to 180 days, half of the "old" EU member states still take far longer, according to data from Cambridge Pharma Consultancy (part of IMS Health).